The resistant macular oedema

The resistant macular oedema.

Fingolimod-associated macular oedema.

Jasani KM, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2016-218912 Description A 54-year-old female with history of relapsing remitting multiple sclerosis (MS) was switched from interferon beta-1A (Avonex, Biogen) to fingolimod (Gilenya, Novartis) therapy after having two clinical relapses within 2 years while on treatment. As part of her treatment protocol, she was referred to the local ophthalm...

Diabetic Macular Oedema

Diabetic macular oedema (DMO) is a major cause of blindness that has an increasing prevalence associated with the general population in diabetes worldwide. In DMO, increased expression of factors including vascular endothelial growth factor (VEGF) disrupts the blood– retina barrier causing leakage and accumulation of extracellular fluid in the macula with resultant loss of vision. Focal and gri...

Retina diabetic Macular oedema

© Touch MEdical MEdia 2013 45 Abstract diabetic macular oedema (dMo) is a leading cause of vision loss in the working-age population worldwide. Numerous early studies suggest an important role for intravitreal anti-VEGF agents such as bevacizumab in the management of dMo. We reviewed manuscripts that had investigated pharmacokinetic, efficacy, safety, dose and frequency of intravitreal bevacizu...

Review Diabetic Macular Oedema

In recent years, several intravitreal drug applications have become available for the treatment of diabetic macular oedema (DME). This review aims to summarise and compare available results. Based on a PubMed search, appropriate studies or reviews were evaluated. Clinical trial data suggest that the intravitreal administration of both vascular endothelial growth factor (VEGF) inhibitors and cor...